title: Lornoxicam-induced acute generalized exanthematous pustulosis.
authors.affiliation: Department of Pharmacology, Faculty of Medicine, University of Sousse, Sousse, Tunisia. larifsofiene@gmail.com.
authors.forename: Sofiene
authors.initials: S
authors.lastname: Larif
authors.affiliation: Department of Pharmacology, Faculty of Medicine, University of Sousse, Sousse, Tunisia.
authors.forename: Raoudha
authors.initials: R
authors.lastname: Slim
authors.affiliation: Department of Pharmacology, Faculty of Medicine, University of Sousse, Sousse, Tunisia.
authors.forename: Neila
authors.initials: N
authors.lastname: Fathallah
authors.affiliation: Department of Dermatology, Frarhet Hached Hospital, Sousse, Tunisia.
authors.forename: Najet
authors.initials: N
authors.lastname: Ghariani
authors.affiliation: Department of Intensive Medical Care, Sahloul Hospital, Sousse, Tunisia.
authors.forename: Houssem
authors.initials: H
authors.lastname: Hmouda
authors.affiliation: Department of Pharmacology, Faculty of Medicine, University of Sousse, Sousse, Tunisia.
authors.forename: Chaker
authors.initials: C
authors.lastname: Ben Salem
mesh_terms: D017255:Acitretin / Q000008:administration & dosage*; D000208:Acute Disease; D056150:Acute Generalized Exanthematous Pustulosis / Q000209:etiology* / Q000473:pathology; D000328:Adult; D001707:Biopsy, Needle; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D017116:Low Back Pain / Q000175:diagnosis / Q000188:drug therapy*; D010894:Piroxicam / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D011565:Psoriasis / Q000175:diagnosis / Q000188:drug therapy*; D018570:Risk Assessment; D028761:Withholding Treatment
chemical_list: D010894:Piroxicam; C059451:lornoxicam; D017255:Acitretin